Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pholcodine→

Pholcodine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
509-67-1
Molecular formula
C23H30N2O4
Molecular weight
398.5 g/mol
Drug class
Opioid antitussivecentrally acting cough-reflex suppressant
Mechanism of action
Acts centrally on the medullary cough centre, reducing the neural signals that trigger cough. It has opioid-related pharmacology but is used primarily as an antitussive rather than as an analgesic.
Indications / reported uses
  • Historically used for symptomatic treatment of non-productive (dry) cough in adults and children, including in combination cold-and-flu products.
  • Pholcodine-containing medicines were withdrawn from the EU market in 2023 because use in the preceding 12 months was associated with an increased risk of peri-anaesthetic anaphylaxis to neuromuscular blocking agents. Current availability and restrictions vary by jurisdiction.

Sources: https://www.ema.europa.eu/en/medicines/human/referrals/pholcodine-containing-medicinal-products · https://www.ema.europa.eu/en/news/ema-recommends-withdrawal-pholcodine-medicines-eu-market · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pholcodine Environmental Risk Assessment (ERA) (the Pholcodine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.